RU2010111758A - Иммуногенные композиции и способы - Google Patents

Иммуногенные композиции и способы Download PDF

Info

Publication number
RU2010111758A
RU2010111758A RU2010111758/10A RU2010111758A RU2010111758A RU 2010111758 A RU2010111758 A RU 2010111758A RU 2010111758/10 A RU2010111758/10 A RU 2010111758/10A RU 2010111758 A RU2010111758 A RU 2010111758A RU 2010111758 A RU2010111758 A RU 2010111758A
Authority
RU
Russia
Prior art keywords
seq
immunogenic peptide
polypeptide according
antigenic epitope
amino acid
Prior art date
Application number
RU2010111758/10A
Other languages
English (en)
Other versions
RU2468034C2 (ru
Inventor
Джералд В. ФИШЕР (US)
Джералд В. ФИШЕР
Люк Т. ДАУМ (US)
Люк Т. ДАУМ
Original Assignee
ЛОНГХОРН ВЭКСИНС ЭНД ДИАГНОСТИКС ЭлЭлСи (US)
ЛОНГХОРН ВЭКСИНС ЭНД ДИАГНОСТИКС ЭлЭлСи
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ЛОНГХОРН ВЭКСИНС ЭНД ДИАГНОСТИКС ЭлЭлСи (US), ЛОНГХОРН ВЭКСИНС ЭНД ДИАГНОСТИКС ЭлЭлСи filed Critical ЛОНГХОРН ВЭКСИНС ЭНД ДИАГНОСТИКС ЭлЭлСи (US)
Publication of RU2010111758A publication Critical patent/RU2010111758A/ru
Application granted granted Critical
Publication of RU2468034C2 publication Critical patent/RU2468034C2/ru

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/085—Staphylococcus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/09—Lactobacillales, e.g. aerococcus, enterococcus, lactobacillus, lactococcus, streptococcus
    • A61K39/092—Streptococcus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/102—Pasteurellales, e.g. Actinobacillus, Pasteurella; Haemophilus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/145—Orthomyxoviridae, e.g. influenza virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/33—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Clostridium (G)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/35—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Mycobacteriaceae (F)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5252—Virus inactivated (killed)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5254—Virus avirulent or attenuated
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A61K2039/541—Mucosal route
    • A61K2039/543—Mucosal route intranasal
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55566—Emulsions, e.g. Freund's adjuvant, MF59
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
    • A61K2039/575—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2 humoral response
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • A61K2039/6031—Proteins
    • A61K2039/6037—Bacterial toxins, e.g. diphteria toxoid [DT], tetanus toxoid [TT]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • A61K2039/6031—Proteins
    • A61K2039/6043—Heat shock proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • A61K2039/6031—Proteins
    • A61K2039/6068—Other bacterial proteins, e.g. OMP
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/70—Multivalent vaccine
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/40—Fusion polypeptide containing a tag for immunodetection, or an epitope for immunisation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/40—Fusion polypeptide containing a tag for immunodetection, or an epitope for immunisation
    • C07K2319/42—Fusion polypeptide containing a tag for immunodetection, or an epitope for immunisation containing a HA(hemagglutinin)-tag
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/16011—Orthomyxoviridae
    • C12N2760/16111—Influenzavirus A, i.e. influenza A virus
    • C12N2760/16122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/16011—Orthomyxoviridae
    • C12N2760/16111—Influenzavirus A, i.e. influenza A virus
    • C12N2760/16134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/16011—Orthomyxoviridae
    • C12N2760/16111—Influenzavirus A, i.e. influenza A virus
    • C12N2760/16161—Methods of inactivation or attenuation

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Virology (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Immunology (AREA)
  • Microbiology (AREA)
  • Genetics & Genomics (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pulmonology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Biomedical Technology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

1. Иммуногенный пептид или полипептид, содержащий ! (a) (i) первый антигенный эпитоп длиной от 6 до приблизительно 70 аминокислот, состоящий из первой аминокислотной последовательности, которая по крайней мере на 95% идентична первой последовательности, выбранной из SEQ ID NO: 1, SEQ ID NO: 11 или SEQ ID NO: 16; и (ii) второй антигенный эпитоп длиной от 6 до приблизительно 70 аминокислот, состоящий из второй аминокислотной последовательности, которая по крайней мере на 95% идентична второй последовательности, выбранной из SEQ ID NO: 1, SEQ ID NO: 11 или SEQ ID NO: 16; или ! (b) первый и второй антигенный эпитопы, каждый из которых имеет длину от 6 до приблизительно 50 аминокислот и состоит из первой аминокислотной последовательности, которая по крайней мере на 95% идентична аминокислотной последовательности, выбранной из SEQ ID NO: 1, SEQ ID NO: 11 или SEQ ID NO: 16. ! 2. Иммуногенный пептид или полипептид по п.1, где патогеном является бактерия, вирус, простейшее, дрожжи или гриб. ! 3. Иммуногенный пептид или полипептид по п.2, в котором первый антигенный эпитоп, по существу, гомологичен по крайней мере первому белку первого вирусного или микробного патогена, а второй антигенный эпитоп, по существу, гомологичен по крайней мере второму белку второго вирусного или микробного патогена. ! 4. Иммуногенный пептид или полипептид по п.1, в котором первый антигенный эпитоп имеет длину от 6 до приблизительно 50 аминокислот и состоит из аминокислотной последовательности, которая по крайней мере на 95% идентична последовательности, выбранной из SEQ ID NO: 1, SEQ ID NO: 11 или SEQ ID NO: 16. ! 5. Иммуногенный пептид или полипептид по п.1, в котором каждый из первого и второго антигенных эпитопов содержит по крайней ме�

Claims (24)

1. Иммуногенный пептид или полипептид, содержащий
(a) (i) первый антигенный эпитоп длиной от 6 до приблизительно 70 аминокислот, состоящий из первой аминокислотной последовательности, которая по крайней мере на 95% идентична первой последовательности, выбранной из SEQ ID NO: 1, SEQ ID NO: 11 или SEQ ID NO: 16; и (ii) второй антигенный эпитоп длиной от 6 до приблизительно 70 аминокислот, состоящий из второй аминокислотной последовательности, которая по крайней мере на 95% идентична второй последовательности, выбранной из SEQ ID NO: 1, SEQ ID NO: 11 или SEQ ID NO: 16; или
(b) первый и второй антигенный эпитопы, каждый из которых имеет длину от 6 до приблизительно 50 аминокислот и состоит из первой аминокислотной последовательности, которая по крайней мере на 95% идентична аминокислотной последовательности, выбранной из SEQ ID NO: 1, SEQ ID NO: 11 или SEQ ID NO: 16.
2. Иммуногенный пептид или полипептид по п.1, где патогеном является бактерия, вирус, простейшее, дрожжи или гриб.
3. Иммуногенный пептид или полипептид по п.2, в котором первый антигенный эпитоп, по существу, гомологичен по крайней мере первому белку первого вирусного или микробного патогена, а второй антигенный эпитоп, по существу, гомологичен по крайней мере второму белку второго вирусного или микробного патогена.
4. Иммуногенный пептид или полипептид по п.1, в котором первый антигенный эпитоп имеет длину от 6 до приблизительно 50 аминокислот и состоит из аминокислотной последовательности, которая по крайней мере на 95% идентична последовательности, выбранной из SEQ ID NO: 1, SEQ ID NO: 11 или SEQ ID NO: 16.
5. Иммуногенный пептид или полипептид по п.1, в котором каждый из первого и второго антигенных эпитопов содержит по крайней мере, по существу, одинаковую первичную аминокислотную последовательность.
6. Иммуногенный пептид или полипептид по п.1, в котором первый антигенный эпитоп, по существу, гомологичен по крайней мере первому белку двух или более различных видов одного и того же патогена.
7. Иммуногенный пептид или полипептид по п.1, в котором первый антигенный эпитоп специфичен для первого белка или пептида M1, M2, HA, NA, PB1, PB2, PspA, PspC, M2e, НА или NA вируса гриппа, а второй антигенный эпитоп специфичен для второго отличного белка или пептида M1, M2, HA, NA, PB1, PB2, PspA, PspC, M2e, НА или NA вируса гриппа.
8. Иммуногенный пептид или полипептид по п.1, в котором первый антигенный эпитоп специфичен для первого штамма или серотипа вируса гриппа, а второй антигенный эпитоп специфичен для второго отличного штамма или серотипа вируса гриппа.
9. Иммуногенный пептид или полипептид по п.1, в котором первый антигенный эпитоп содержит выделенный антигенный пептид длиной от 6 до приблизительно 30 аминокислот, который состоит из аминокислотной последовательности, которая по крайней мере на 95% идентична последовательности, выбранной из SEQ ID NO: 1, SEQ ID NO: 11 или SEQ ID NO: 16, а второй антигенный эпитоп включает выделенный антигенный пептид длиной от 6 до приблизительно 30 аминокислот, который состоит из аминокислотной последовательности, которая по крайней мере на 95% идентична другой последовательности, выбранной из SEQ ID NO: 1, SEQ ID NO: 11 и SEQ ID NO: 16.
10. Иммуногенный пептид или полипептид по п.1, дополнительно содержащий по крайней мере первую последовательность Т-клеточного эпитопа, которая содержит столбнячный анатоксин, дифтерийный анатоксин, полисахарид, липопротеин или их производное или комбинацию.
11. Выделенный полинуклеотид, который кодирует иммуногенный пептид или полипептид по любому пп.1-10.
12. Выделенный полинуклеотид по п.11, содержащийся внутри рекомбинантного экспрессионного вектора.
13. Выделенный полинуклеотид по п.11 или 12, содержащийся внутри рекомбинантного вируса, вириона или вирусной частицы.
14. Выделенное антитело или его антигенсвязывающий фрагмент, которые специфически связываются с иммуногенным пептидом или полипептидом по любому из пп.1-10.
15. Антитело или его антигенсвязывающий фрагмент по п.14, которые выбирают из группы, состоящей из антитела человека, химерного антитела, антигенсвязывающего фрагмента антитела человека, гуманизированного антитела, антигенсвязывающего фрагмента гуманизированного антитела, химерного гуманизированного антитела, антигенсвязывающего фрагмента химерного гуманизированного антитела, поликлональной сыворотки, моноклонального антитела, Fab-фрагмента, Fab'-фрагмента, F(ab')2-фрагмента и Fv-фрагмента.
16. Композиция, содержащая (а) активный иммуногенный компонент, содержащий (i) иммуногенный пептид или полипептид по любому из пп.1-10; (ii) выделенный полинуклеотид по любому из пп.11-13 или (iii) выделенное антитело по п.14 или 15, или любую их комбинацию; и (b) фармацевтически приемлемый буфер, разбавитель или носитель.
17. Композиция по п.16, составленная для введения в клетку-хозяина животного и предпочтительно клетку-хозяина млекопитающего.
18. Композиция по п.16 или 17 для лечения патогенной инфекции у млекопитающего.
19. Композиция по п.16 для применения для диагностики, профилактики или лечения.
20. Применение композиции по любому из пп.16-19 для производства лекарственного средства или вакцины для профилактики или лечения и, в частности, лекарственного средства для диагностики, лечения, предупреждения или уменьшения интенсивности одного или нескольких симптомов вирусной или микробной инфекции у млекопитающего и предпочтительно человека.
21. Способ индукции у животного иммунологической реакции, включающий введение композиции, которая содержит иммуногенный пептид или полипептид по любому из пп.1-10, в количестве, эффективном для индукции иммунологической реакции.
22. Способ профилактики или контроля вспышки гриппозной инфекции в отобранной популяции млекопитающих, включающий введение чувствительному или подверженному риску члену популяции композиции, которая содержит иммуногенный пептид или полипептид по любому из пп.1-10 в количестве, эффективном для предупреждения или контроля вспышки гриппозной инфекции в популяции.
23. Способ стимуляции иммунной системы индивидуума для индукции защитной иммунной реакции против патогенной инфекции, включающий введение индивидууму иммунологически эффективного количества композиции, содержащей иммуногенный пептид или полипептид по любому из пп.1-10 в течение периода времени, который является достаточным для стимулирования иммунной системы индивидуума с индукцией защитной иммунной реакции против патогена.
24. Способ индукции защитной иммунной реакции против вируса гриппа у нуждающегося в этом млекопитающего, включающий введение млекопитающему количества композиции, которая содержит иммуногенный пептид или полипептид по любому из пп.1-10, эффективного для индукции защитной иммунной реакции против вируса гриппа у млекопитающего.
RU2010111758/10A 2007-08-27 2008-08-27 Иммуногенные композиции и способы RU2468034C2 (ru)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US96814507P 2007-08-27 2007-08-27
US60/968,145 2007-08-27
PCT/US2008/074521 WO2009029686A1 (en) 2007-08-27 2008-08-27 Immunogenic compositions and methods

Publications (2)

Publication Number Publication Date
RU2010111758A true RU2010111758A (ru) 2011-10-10
RU2468034C2 RU2468034C2 (ru) 2012-11-27

Family

ID=40002933

Family Applications (1)

Application Number Title Priority Date Filing Date
RU2010111758/10A RU2468034C2 (ru) 2007-08-27 2008-08-27 Иммуногенные композиции и способы

Country Status (7)

Country Link
US (3) US8821885B2 (ru)
EP (3) EP3058954B1 (ru)
AU (1) AU2008293504B2 (ru)
CA (2) CA2976814C (ru)
RU (1) RU2468034C2 (ru)
WO (1) WO2009029686A1 (ru)
ZA (2) ZA201001412B (ru)

Families Citing this family (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8097419B2 (en) 2006-09-12 2012-01-17 Longhorn Vaccines & Diagnostics Llc Compositions and method for rapid, real-time detection of influenza A virus (H1N1) swine 2009
US8080645B2 (en) 2007-10-01 2011-12-20 Longhorn Vaccines & Diagnostics Llc Biological specimen collection/transport compositions and methods
US9481912B2 (en) 2006-09-12 2016-11-01 Longhorn Vaccines And Diagnostics, Llc Compositions and methods for detecting and identifying nucleic acid sequences in biological samples
US8652782B2 (en) 2006-09-12 2014-02-18 Longhorn Vaccines & Diagnostics, Llc Compositions and methods for detecting, identifying and quantitating mycobacterial-specific nucleic acids
US11041215B2 (en) 2007-08-24 2021-06-22 Longhorn Vaccines And Diagnostics, Llc PCR ready compositions and methods for detecting and identifying nucleic acid sequences
US9683256B2 (en) 2007-10-01 2017-06-20 Longhorn Vaccines And Diagnostics, Llc Biological specimen collection and transport system
AU2008293504B2 (en) 2007-08-27 2012-04-12 Longhorn Vaccines & Diagnostics, Llc Immunogenic compositions and methods
US10004799B2 (en) 2007-08-27 2018-06-26 Longhorn Vaccines And Diagnostics, Llc Composite antigenic sequences and vaccines
US11041216B2 (en) 2007-10-01 2021-06-22 Longhorn Vaccines And Diagnostics, Llc Compositions and methods for detecting and quantifying nucleic acid sequences in blood samples
DK2535428T3 (en) 2007-10-01 2015-11-23 Longhorn Vaccines & Diagnostics Llc Biological prøvesamlings- and transport system, and methods of using
US8658180B2 (en) 2008-08-15 2014-02-25 Mark A. Miller Vaccines against influenza virus
US20120076811A1 (en) * 2009-03-26 2012-03-29 The Johns Hopkins University Immunodominant compositions and methods of use therefor
CA2793772A1 (en) * 2010-03-26 2011-09-29 Emergent Product Development Gaithersburg Inc. Ectodomains of influenza matrix 2 protein, expression system, and uses thereof
US9205144B2 (en) * 2011-06-03 2015-12-08 Dana-Farber Cancer Institute, Inc. Identification of conserved peptide blocks in homologous polypeptides
CN104203272A (zh) * 2012-01-26 2014-12-10 长角牛疫苗和诊断有限责任公司 复合抗原序列及疫苗
EP3153523A3 (en) * 2012-03-02 2017-05-03 Icahn School of Medicine at Mount Sinai Variants of prothymosin alpha and methods of using same
US9808517B2 (en) * 2012-04-06 2017-11-07 Cornell University Subunit vaccine delivery platform for robust humoral and cellular immune responses
RU2536956C1 (ru) * 2013-08-05 2014-12-27 Федеральное государственное бюджетное учреждение "Научно-исследовательский институт пульмонологии Федерального медико-биологического агентства" Противовирусное однодоменное мини-антитело, нуклеотидная последовательность, экспрессирующий рекомбинантный вирусный вектор, фармацевтическая композиция и способ профилактики или терапии гриппа типа а
WO2015073801A1 (en) * 2013-11-14 2015-05-21 Duke University Tetanus toxoid and ccl3 improve dc vaccines
CA2985652C (en) 2015-05-14 2020-03-10 Gerald W. FISHER Rapid methods for the extraction of nucleic acids from biological samples
KR20200038339A (ko) * 2015-09-10 2020-04-10 인벤트프라이즈 엘엘씨 다가 vlp 접합체
WO2017201390A1 (en) * 2016-05-19 2017-11-23 The Regents Of The University Of Michigan Novel adjuvant compositions
WO2018080889A1 (en) * 2016-10-31 2018-05-03 Georgia State University Research Foundation, Inc. A virus like particle of hepatitis b virus pre-s protein
JP2020515283A (ja) 2016-12-28 2020-05-28 インブバックス，インコーポレーテッド インフルエンザワクチン
EP3730620A4 (en) * 2017-12-21 2022-01-05 Green Biomed, Inc. CROSS-IMMUNIZATION ANTIGENIC VACCINE AND PROCESS FOR PREPARATION
KR20220137737A (ko) 2020-02-06 2022-10-12 롱혼 백신즈 앤드 다이어그나스틱스, 엘엘씨 미생물 감염을 치료 및 예방하기 위한 면역원성 조성물
EP4301406A1 (en) * 2021-03-04 2024-01-10 Longhorn Vaccines and Diagnostics, LLC Vaccines for the treatment and prevention of zoonotic infections
CA3238197A1 (en) * 2021-11-12 2023-05-19 Longhorn Vaccines And Diagnostics, Llc Immunogenic compositions and vaccines in the treatment and prevention of infections
DE202022104396U1 (de) 2022-08-02 2022-08-08 Sanjay Kumar Eine Polypharmazeutische Formulierung als Immunitätsverstärker
WO2024036135A2 (en) * 2022-08-09 2024-02-15 Longhorn Vaccines And Diagnostics, Llc Vaccines for the treatment and prevention of seasonal and emerging infections

Family Cites Families (236)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US1307416A (en) 1919-06-24 James k
US2697373A (en) 1952-05-08 1954-12-21 Leblond Mach Tool Co R K Tracer controlled facing lathe
HU171609B (hu) * 1975-12-30 1978-02-28 Mueszeripari Muevek Lab Apparatura dlja opredelenija nevraminidazy infljuehncii
US4196265A (en) 1977-06-15 1980-04-01 The Wistar Institute Method of producing antibodies
US4235244A (en) 1978-07-27 1980-11-25 Medi-Tech, Incorporated Microbiological specimen sampling device
FR2450877A1 (fr) * 1979-03-06 1980-10-03 Inst Nat Sante Rech Med Nouveaux tests par agglutination pour la detection des virus de la grippe, et reactifs pour la realisation de ces tests
US4315073A (en) * 1979-10-26 1982-02-09 Cutter Laboratories, Inc. Titration of serum influenza antibody using plaque reduction neutralization test
US4372945A (en) 1979-11-13 1983-02-08 Likhite Vilas V Antigen compounds
US4554101A (en) 1981-01-09 1985-11-19 New York Blood Center, Inc. Identification and preparation of epitopes on antigens and allergens on the basis of hydrophilicity
IL61904A (en) 1981-01-13 1985-07-31 Yeda Res & Dev Synthetic vaccine against influenza virus infections comprising a synthetic peptide and process for producing same
US4371091A (en) 1981-01-21 1983-02-01 Apollo Molded Products Double-seal molded plastic screw cap
US4356170A (en) 1981-05-27 1982-10-26 Canadian Patents & Development Ltd. Immunogenic polysaccharide-protein conjugates
DE3176206D1 (en) * 1981-07-31 1987-06-25 Sinai School Medicine Assay for viruses
US4596792A (en) * 1981-09-04 1986-06-24 The Regents Of The University Of California Safe vaccine for hepatitis containing polymerized serum albumin
CH652145A5 (de) 1982-01-22 1985-10-31 Sandoz Ag Verfahren zur in vitro-herstellung von hybridomen welche humane monoklonale antikoerper erzeugen.
US4744982A (en) 1982-08-24 1988-05-17 Hunter Kenneth W Human monoclonal antibody reactive with polyribosylribitol phosphate
US4954449A (en) 1982-08-24 1990-09-04 The United States Of America As Represented By The Secretary Of The Army Human monoclonal antibody reactive with polyribosylribitol phosphate
JPS5938877A (ja) * 1982-08-30 1984-03-02 Musashi Eng Kk 紙葉判別方法
DK154394C (da) 1982-10-21 1989-04-24 Apv Pasilac As Fremgangsmaade til at foroege kapaciteten af anlaeg for membranfiltrering af maelk eller maelkeprodukter til foderstoffer eller vaekstmedier.
US4529702A (en) 1983-03-28 1985-07-16 Her Majesty The Queen In Right Of Canada, As Represented By The Minister Of National Defence Transport medium for microorganisms
US4746490A (en) 1983-09-22 1988-05-24 Saneii Hossain H Solid phase peptide synthesizer
US4634666A (en) 1984-01-06 1987-01-06 The Board Of Trustees Of The Leland Stanford Junior University Human-murine hybridoma fusion partner
US4599231A (en) * 1984-03-09 1986-07-08 Scripps Clinic And Research Foundation Synthetic hepatitis B virus vaccine including both T cell and B cell determinants
US4599230A (en) 1984-03-09 1986-07-08 Scripps Clinic And Research Foundation Synthetic hepatitis B virus vaccine including both T cell and B cell determinants
US4668476A (en) 1984-03-23 1987-05-26 Applied Biosystems, Inc. Automated polypeptide synthesis apparatus
US5186898A (en) 1984-03-23 1993-02-16 Applied Biosystems, Inc. Automated polypeptide synthesis apparatus
US4608251A (en) * 1984-11-09 1986-08-26 Pitman-Moore, Inc. LHRH analogues useful in stimulating anti-LHRH antibodies and vaccines containing such analogues
US4883750A (en) 1984-12-13 1989-11-28 Applied Biosystems, Inc. Detection of specific sequences in nucleic acids
US4683202A (en) 1985-03-28 1987-07-28 Cetus Corporation Process for amplifying nucleic acid sequences
US4683195A (en) 1986-01-30 1987-07-28 Cetus Corporation Process for amplifying, detecting, and/or-cloning nucleic acid sequences
US4601903A (en) 1985-05-01 1986-07-22 The United States Of America As Represented By The Department Of Health And Human Services Vaccine against Neisseria meningitidis Group B serotype 2 invasive disease
CA1264275A (en) 1985-09-04 1990-01-09 Wadley Technologies, Inc. Stabilization of specimens for microbial analysis
US5503841A (en) 1985-09-20 1996-04-02 Cetus Oncology Corporation Human IL-2 as a vaccine adjuvant
US5643565A (en) 1985-09-20 1997-07-01 Chiron Corporation Human IL-2 as a vaccine adjuvant
US4996143A (en) 1985-12-23 1991-02-26 Syngene, Inc. Fluorescent stokes shift probes for polynucleotide hybridization
US4803998A (en) 1986-01-27 1989-02-14 Ncs Diagnostics, Inc. Swab retaining vial cap and method of use
US4800159A (en) 1986-02-07 1989-01-24 Cetus Corporation Process for amplifying, detecting, and/or cloning nucleic acid sequences
MY102517A (en) 1986-08-27 1992-07-31 Conoco Specialty Prod Cyclone separator
US4707450A (en) 1986-09-25 1987-11-17 Nason Frederic L Specimen collection and test unit
US4981782A (en) * 1987-05-14 1991-01-01 Sri International Synthetic peptides for diagnosis and prevention of influenza virus infection and their use
EP0313224A1 (en) 1987-09-28 1989-04-26 Children's Hospital Medical Center Human cell lines of epithelial lung adenocarcinoma origin, human proteins and methods
US5202238A (en) 1987-10-27 1993-04-13 Oncogen Production of chimeric antibodies by homologous recombination
GB8801338D0 (en) 1988-01-21 1988-02-17 Quadrant Bioresources Ltd Preservation of viruses
JP2849632B2 (ja) 1988-04-08 1999-01-20 社団法人北里研究所 ワクチン製剤
US5163441A (en) 1988-06-09 1992-11-17 Becton, Dickinson And Company Polyurethane biological sample collection and transport device and its use
US5091316A (en) 1988-06-09 1992-02-25 Becton, Dickinson And Company Biological sample collection and transport device
US5234809A (en) 1989-03-23 1993-08-10 Akzo N.V. Process for isolating nucleic acid
US5549910A (en) 1989-03-31 1996-08-27 The Regents Of The University Of California Preparation of liposome and lipid complex compositions
US5243030A (en) * 1989-05-24 1993-09-07 Sri International Conjugates of a synthetic peptide for diagnosis and prevention of influenza virus infection
US5136019A (en) * 1989-05-24 1992-08-04 Sri International Synthetic peptides for diagnosis and prevention of influenza virus infection and their use
HU212924B (en) 1989-05-25 1996-12-30 Chiron Corp Adjuvant formulation comprising a submicron oil droplet emulsion
US5128247A (en) 1989-08-14 1992-07-07 Board Of Regents, The University Of Texas System Methods for isolation of nucleic acids from eukaryotic and prokaryotic sources
DE3929144A1 (de) * 1989-09-02 1991-03-07 Behringwerke Ag Nachweis von influenza-a-virus durch polymerase-kettenreaktion (pcr) nach reverser transkription eines bereichs des viralen haemagglutinin-gens
US5252334A (en) 1989-09-08 1993-10-12 Cygnus Therapeutic Systems Solid matrix system for transdermal drug delivery
US5663055A (en) * 1989-12-29 1997-09-02 Oklahoma Medical Research Foundation Methods for diagnosing human influenza and 4-position modified chromogenic N-acetylneuraminic acid substrated for use therein
JP3218637B2 (ja) 1990-07-26 2001-10-15 大正製薬株式会社 安定なリポソーム水懸濁液
CA2089562A1 (en) 1990-08-14 1992-02-15 Lex M. Cowsert Inhibition of influenza virus type a, ann arbor strain h2n2 by antisense oligonucleotides
JP2958076B2 (ja) 1990-08-27 1999-10-06 株式会社ビタミン研究所 遺伝子導入用多重膜リポソーム及び遺伝子捕捉多重膜リポソーム製剤並びにその製法
US5168039A (en) 1990-09-28 1992-12-01 The Board Of Trustees Of The University Of Arkansas Repetitive DNA sequence specific for mycobacterium tuberculosis to be used for the diagnosis of tuberculosis
US6632432B1 (en) 1990-10-22 2003-10-14 Henry M. Jackson Foundation For The Advancement Of Military Medicine Directed human immune globulin for the prevention and treatment of staphylococcal infections
US7279162B1 (en) 1990-10-22 2007-10-09 Henry M. Jackson Foundation For The Advancement Of Military Medicine Isolated broadly reactive opsonic immunoglobulin for treating a pathogenic coagulase-negative staphylococcus infection
US5571511A (en) 1990-10-22 1996-11-05 The U.S. Government Broadly reactive opsonic antibodies that react with common staphylococcal antigens
US20080139789A1 (en) 1990-10-22 2008-06-12 Henry M. Jackson Foundation For The Advancement Of Military Medicine Isolated Broadly Reactive Opsonic Immunoglobulin for Treating a Pathogenic Coagulase-Negative Staphylococcus Infection
US5252458A (en) 1990-12-31 1993-10-12 Symex Corp. Method for visually detecting the presence of a virus in a clinical specimen
US5399363A (en) 1991-01-25 1995-03-21 Eastman Kodak Company Surface modified anticancer nanoparticles
US5145684A (en) 1991-01-25 1992-09-08 Sterling Drug Inc. Surface modified drug nanoparticles
WO1992016619A1 (en) 1991-03-19 1992-10-01 Us Army Expression of influenza nucleoprotein antigens in baculovirus
US5290686A (en) * 1991-07-31 1994-03-01 The United States Of America As Represented By The Department Of Health And Human Services Expression of influenza a M2 protein in baculovirus
DE69231853T2 (de) 1991-11-07 2001-09-13 Nanotronics Inc Hybridisierung von mit chromophoren und fluorophoren konjugierten polynukleotiden zur erzeugung eines donor-zu-donor energietransfersystems
IL103928A0 (en) * 1991-12-11 1993-04-04 American Home Prod Expression of specific immunogens using viral antigens
US6689363B1 (en) * 1992-01-29 2004-02-10 Epimmune Inc. Inducing cellular immune responses to hepatitis B virus using peptide and nucleic acid compositions
US5679356A (en) 1992-07-08 1997-10-21 Schering Corporation Use of GM-CSF as a vaccine adjuvant
US5589174A (en) * 1992-09-17 1996-12-31 Takara Shuzo Co., Ltd. Anti-human influenza virus antibody
US6337070B1 (en) * 1993-04-29 2002-01-08 Takara Shuzo Co., Ltd. Polypeptides for use in generating anti-human influenza virus antibodies
EP0621339B1 (en) 1992-09-17 2001-10-24 Takara Shuzo Co. Ltd. Immunogenic human influenza A virus haemagglutinin polypeptides
SE9202968L (sv) 1992-10-09 1994-04-10 Replico Medical Ab Nya peptider, diagnostiska antigener, deras användning, vacciner och medikamenter
WO1994017106A1 (en) 1993-01-19 1994-08-04 Pharmacia P-L Biochemicals, Inc. Storage and delivery of purified protein reagents with carrier wax
US5543158A (en) 1993-07-23 1996-08-06 Massachusetts Institute Of Technology Biodegradable injectable nanoparticles
IT1272598B (it) 1993-09-09 1997-06-26 Copan Italia Spa Dispositivo per il prelievo e trasporto di campioni in vitro principalmente per uso diagnostico
JP3828145B2 (ja) 1993-09-22 2006-10-04 ヘンリー エム．ジャクソン ファウンデイション フォー ザ アドバンスメント オブ ミリタリー メディスン 免疫原性構成物の製造のための新規シアン化試薬を使った可溶性炭水化物の活性化方法
NL9400045A (nl) * 1994-01-11 1995-08-01 Univ Gent Influenza vaccin.
JP2996864B2 (ja) 1994-03-30 2000-01-11 寳酒造株式会社 抗体可変領域ｄｎａ
US5741516A (en) 1994-06-20 1998-04-21 Inex Pharmaceuticals Corporation Sphingosomes for enhanced drug delivery
US5702944A (en) 1994-07-25 1997-12-30 Micro Test, Inc. Microbial transport media
US5545555A (en) 1994-07-25 1996-08-13 Microtest, Inc. Microbial transport media
US5612037A (en) * 1994-07-26 1997-03-18 Connaught Laboratories, Inc. Influenza virus subunit conjugates
US6019982A (en) 1994-08-26 2000-02-01 The Administrators Of The Tulane Educational Fund Mutant enterotoxin effective as a non-toxic oral adjuvant
WO1996010389A1 (de) * 1994-09-30 1996-04-11 Mika Pharma Gesellschaft Für Die Entwicklung Und Vermarktung Pharmazeutischer Produkte Mbh Pharmazeutische zusammensetzung
FR2726764B1 (fr) 1994-11-14 1997-01-31 Pasteur Merieux Serums Vacc Adjuvant pour composition vaccinale
DE4443643A1 (de) 1994-12-08 1996-06-13 Henkel Kgaa Anionische Detergensgemische
US5795587A (en) 1995-01-23 1998-08-18 University Of Pittsburgh Stable lipid-comprising drug delivery complexes and methods for their production
US5697899A (en) 1995-02-07 1997-12-16 Gensia Feedback controlled drug delivery system
GB9502489D0 (en) 1995-02-09 1995-03-29 Animal Health Trust Expression of the non-structural protein NS1 of influenza virus and detection of anti-NS1 antibody in serum
IE80468B1 (en) 1995-04-04 1998-07-29 Elan Corp Plc Controlled release biodegradable nanoparticles containing insulin
US5785975A (en) 1995-06-26 1998-07-28 Research Triangle Pharmaceuticals Adjuvant compositions and vaccine formulations comprising same
US5738868A (en) 1995-07-18 1998-04-14 Lipogenics Ltd. Liposome compositions and kits therefor
US5945515A (en) 1995-07-31 1999-08-31 Chomczynski; Piotr Product and process for isolating DNA, RNA and proteins
US6015664A (en) * 1995-11-03 2000-01-18 Mcw Research Foundation Multiplex PCR assay using unequal primer concentrations to detect HPIV 1,2,3 and RSV A,B and influenza virus A, B
AU1689497A (en) 1995-12-29 1997-07-28 University Hospitals Of Cleveland Methods of culturing and assaying a virus
US5795582A (en) 1996-02-07 1998-08-18 Novavax, Inc. Adjuvant properties of poly (amidoamine) dendrimers
ATE238552T1 (de) * 1996-03-01 2003-05-15 Biota Scient Management Verfahren zum nachweis von influenza-virus und dazu verwendbare verbindungen
US5656016A (en) 1996-03-18 1997-08-12 Abbott Laboratories Sonophoretic drug delivery system
US5736333A (en) 1996-06-04 1998-04-07 The Perkin-Elmer Corporation Passive internal references for the detection of nucleic acid amplification products
US5797898A (en) 1996-07-02 1998-08-25 Massachusetts Institute Of Technology Microchip drug delivery devices
US5783208A (en) 1996-07-19 1998-07-21 Theratech, Inc. Transdermal drug delivery matrix for coadministering estradiol and another steroid
US5779708A (en) 1996-08-15 1998-07-14 Cyberdent, Inc. Intraosseous drug delivery device and method
US5719020A (en) * 1996-09-25 1998-02-17 Oklahoma Medical Research Foundation 4,7-dialkoxy N-acetylneuraminic acid derivatives and methods for detection of influenza type A and B viruses in clinical specimens
US6458577B1 (en) 1996-12-27 2002-10-01 University Hospital Of Cleveland Methods of culturing and assaying a virus in a specimen and compositions and cell lines for doing the same
TW570803B (en) * 1997-04-09 2004-01-11 Duphar Int Res Influenza vaccine
ATE346606T1 (de) 1997-05-01 2006-12-15 Protechtion Unltd Inc Nervenwachstumsfaktor als impfstoffadjuvans
US6136585A (en) * 1997-05-02 2000-10-24 Uab Research Foundation Attenuation of negative stranded RNA viruses by rearrangement of genes and uses thereof
US6610293B1 (en) 1997-06-16 2003-08-26 The Henry M. Jackson Foundation For The Advancement Of Military Medicine Opsonic and protective monoclonal and chimeric antibodies specific for lipoteichoic acid of gram positive bacteria
EP0919243A1 (en) 1997-11-25 1999-06-02 Duphar International Research B.V Vaccine containing B subunits of heat-labile enterotoxin (LTB) of Escherichia coli as an adjuvant
GB9725084D0 (en) 1997-11-28 1998-01-28 Medeva Europ Ltd Vaccine compositions
GB9726555D0 (en) 1997-12-16 1998-02-11 Smithkline Beecham Plc Vaccine
FR2775601B1 (fr) 1998-03-03 2001-09-21 Merial Sas Vaccins vivants recombines et adjuves
US6033673A (en) 1998-03-18 2000-03-07 The Administrators Of Tulane Educational Fund Double mutant enterotoxin for use as an adjuvant
US6303081B1 (en) 1998-03-30 2001-10-16 Orasure Technologies, Inc. Device for collection and assay of oral fluids
CN1297352A (zh) * 1998-04-14 2001-05-30 哈桑·朱马 有机磷化合物在治疗和预防性治疗感染中的应用
US6946291B2 (en) * 1998-04-24 2005-09-20 University Hospitals Of Cleveland Mixed cell diagnostic systems
US6280928B1 (en) * 1998-04-24 2001-08-28 Diagnostic Hybrids, Inc. Mixed cell diagnostic systems
US6168915B1 (en) * 1998-04-24 2001-01-02 Diagnostic Hybrids, Inc. Mixed cell diagnostic systems
GB9808932D0 (en) * 1998-04-27 1998-06-24 Chiron Spa Polyepitope carrier protein
US6306404B1 (en) 1998-07-14 2001-10-23 American Cyanamid Company Adjuvant and vaccine compositions containing monophosphoryl lipid A
US6579528B1 (en) * 1998-08-13 2003-06-17 The University Of Pittsburgh - Of The Commonwealth System Of Higher Education Cold-adapted equine influenza viruses
US6482414B1 (en) * 1998-08-13 2002-11-19 The University Of Pittsburgh-Of The Commonwealth System Of Higher Education Cold-adapted equine influenza viruses
EP2266604A3 (en) 1998-10-16 2011-05-11 GlaxoSmithKline Biologicals S.A. Adjuvant systems and vaccines
AU1520300A (en) * 1998-11-05 2000-05-29 Biocryst Pharmaceuticals, Inc. New cyclopentane and cyclopentene compounds and use for detecting influenza virus
JP4499295B2 (ja) 1999-01-28 2010-07-07 サイト パルス サイエンシズ、インコーポレイテッド 細胞内への巨大分子の送達
RU2150281C1 (ru) 1999-03-29 2000-06-10 Научно-исследовательский ветеринарный институт Нечерноземной зоны РФ Способ лечения респираторных болезней телят
WO2000063423A2 (en) * 1999-04-16 2000-10-26 Zymetx, Inc. Viral detection method using viral encoded enzymes and chemiluminescent substrates
WO2000064446A1 (en) 1999-04-26 2000-11-02 Emory University Noscapine derivatives as adjuvant compositions and methods of use thereof
US20090087878A9 (en) * 1999-05-06 2009-04-02 La Rosa Thomas J Nucleic acid molecules associated with plants
US20040031072A1 (en) * 1999-05-06 2004-02-12 La Rosa Thomas J. Soy nucleic acid molecules and other molecules associated with transcription plants and uses thereof for plant improvement
US6312395B1 (en) 1999-06-29 2001-11-06 Innovative Genetic Technology Cell collection and transport
SE9903031D0 (sv) * 1999-08-27 1999-08-27 Eurodiagnostica Ab Peptide mixture and vaccine against a chronic viral infection
EP1081496A1 (en) 1999-08-31 2001-03-07 Becton, Dickinson and Company Flow-through assay for visually detecting the presence of influenza A and B
US6759241B1 (en) 1999-10-04 2004-07-06 University Of Maryland Biotechnology Institute Adjuvant comprising a lipopolysaccharide antagonist
US6627396B1 (en) * 1999-10-28 2003-09-30 The Regents Of The University Of California Influenza sensor
US6602510B1 (en) * 2000-04-05 2003-08-05 Epimmune Inc. HLA class I A2 tumor associated antigen peptides and vaccine compositions
JP2003519197A (ja) * 2000-01-05 2003-06-17 アヴェンティス パストゥール リミテッド 誘導物質および抗原で免疫する前に誘導物質で予備感作することによる、抗原に対する免疫応答の増強
DE10006662A1 (de) * 2000-02-15 2001-08-23 Antigen Produktions Gmbh Gefäß zur Nukleinsäureanalytik
DE10028837A1 (de) 2000-06-15 2001-12-20 Roche Diagnostics Gmbh Verfahren zum Nachweis von Influenza A/B-Viren
US6603908B2 (en) * 2000-08-04 2003-08-05 Alcatel Buffer tube that results in easy access to and low attenuation of fibers disposed within buffer tube
US6942866B2 (en) * 2000-08-16 2005-09-13 Apovia, Inc. Malaria immunogen and vaccine
KR20040066185A (ko) * 2000-08-17 2004-07-23 샤단호칭키타사토겐큐쇼 신규 슈도에리쓰로마이신 유도체
GB0021303D0 (en) 2000-08-30 2000-10-18 Medinnova Sf Use
DE60139136D1 (de) * 2000-10-05 2009-08-13 Hai Kang Life Corp Ltd Kit zum nachweis von nichtpathogenem oder pathogenem influenza-a-virus vom subtyp h5
US6800289B2 (en) * 2000-12-21 2004-10-05 Her Majesty The Queen In Right Of Canada, As Represented By The Minister Of National Defence Strain of the western equine encephalitis virus
WO2002069949A2 (en) 2001-03-06 2002-09-12 Prendergast Patrick T Combination therapy for reduction of toxycity of chemotherapeutic agents
MY134424A (en) 2001-05-30 2007-12-31 Saechsisches Serumwerk Stable influenza virus preparations with low or no amount of thiomersal
AU2002367976B2 (en) 2001-06-05 2007-06-21 The Regents Of The University Of Michigan Nanoemulsion vaccines
US7494771B2 (en) * 2001-07-19 2009-02-24 Geneohm Sciences Canada, Inc. Universal method and composition for the rapid lysis of cells for the release of nucleic acids and their detection
US7361352B2 (en) * 2001-08-15 2008-04-22 Acambis, Inc. Influenza immunogen and vaccine
AU2002325026A1 (en) 2001-09-27 2003-04-07 St. Jude Children's Research Hospital, Inc. Use of neuraminidase inhibitors to prevent flu associated bacterial infections
US7148343B2 (en) * 2001-10-12 2006-12-12 Gentra Systems, Inc. Compositions and methods for using a solid support to purify RNA
US20040071757A1 (en) * 2001-11-20 2004-04-15 David Rolf Inhalation antiviral patch
CA2469132A1 (en) 2001-12-11 2003-07-03 Merck & Co., Inc. Staphylococcus aureus exopolysaccharide and process
US20030119209A1 (en) * 2001-12-21 2003-06-26 Kaylor Rosann Marie Diagnostic methods and devices
US6881835B2 (en) * 2002-01-04 2005-04-19 Dr. Chip Biotechnology Inc. Detection of respiratory viruses
JP4515767B2 (ja) 2002-01-31 2010-08-04 ユニバーシティ・オブ・ユタ 非標的核酸依存性増幅の低減：反復核酸配列の増幅
US7351413B2 (en) * 2002-02-21 2008-04-01 Lorantis, Limited Stabilized HBc chimer particles as immunogens for chronic hepatitis
CA2477979A1 (en) * 2002-03-05 2003-09-18 Transave, Inc. An inhalation system for treatment of intracellular infections
EP1490099A4 (en) 2002-03-13 2006-02-08 Kirin Brewery HUMAN MONOCLONAL ANTIBODIES AGAINST THE INFLUENZA VIRUS PROTEIN M2 AND METHODS OF MAKING AND USING THE SAME
US20050170334A1 (en) * 2002-03-13 2005-08-04 Toshifumi Mikayama Human monoclonal antibodies to influenza M2 protein and methods of making and using same
US7745180B2 (en) 2002-04-24 2010-06-29 Hitachi Chemical Co., Ltd. Device and method for high-throughput quantification of mRNA from whole blood
US6610474B1 (en) 2002-04-25 2003-08-26 University Hospitals Of Cleveland Cells for detection of influenza and parainfluenza viruses
GB0210766D0 (en) 2002-05-10 2002-06-19 Genovision As Isolating nucleic acid
US7122640B2 (en) 2002-06-10 2006-10-17 Phynexus, Inc. Open channel solid phase extraction systems and methods
WO2004003143A2 (en) * 2002-06-26 2004-01-08 Advanced Bionutrition Corporation Viruses and virus-like particles for multiple antigen and target display
WO2004002451A1 (fr) * 2002-06-28 2004-01-08 Fang Chen Suppositoire a liberation controlee utilise dans un canal secreteur de lait
AU2003248921A1 (en) 2002-07-09 2004-01-23 Point Therapeutics, Inc. Boroproline compound combination therapy
WO2004022770A2 (en) * 2002-09-05 2004-03-18 Invitrogen Corporation Compositions and methods for synthesizing nucleic acids
AU2003290867A1 (en) 2002-11-12 2004-06-03 The Brigham And Women's Hospital, Inc. Methods and products for treating staphylococcal infections
AU2003294401C1 (en) 2002-11-22 2008-09-18 Ansun Biopharma, Inc. Broad spectrum anti-viral therapeutics and prophylaxis
US7311671B2 (en) 2002-11-29 2007-12-25 Access Bio, Inc. Device for sample collection and storage
EP2280086A1 (en) * 2002-12-13 2011-02-02 Geneohm Sciences Canada Inc. Biological reagents and methods to verify the efficiency of sample preparation and nucleic acid amplification and/or detection
EP1594536B1 (en) * 2003-01-30 2009-03-25 Novartis Vaccines and Diagnostics, Inc. Adjuvanted influenza vaccine
US7517697B2 (en) 2003-02-05 2009-04-14 Applied Biosystems, Llc Compositions and methods for preserving RNA in biological samples
BRPI0407877A (pt) 2003-03-07 2006-03-01 Merck & Co Inc conjugado de peptìdeo-proteìna, vacina para a prevenção ou melhora da infecção pelo vìrus influenza, e, método para induzir um resposta imune em um paciente
US7547512B2 (en) * 2003-03-24 2009-06-16 The University Of Hong Kong High-throughput diagnostic assay for the human virus causing severe acute respiratory syndrome (SARS)
ZA200508482B (en) 2003-03-26 2007-03-28 Recepticon Aps Use of compounds for the prevention of drug-induced cell toxicity
ES2363501T3 (es) * 2003-05-07 2011-08-05 Coris Bioconcept Sprl Dispositivo oligocromático de un paso y procedimiento de uso.
WO2005018539A2 (en) * 2003-06-16 2005-03-03 Medimmune Vaccines, Inc. Influenza hemagglutinin and neuraminidase variants
US8592197B2 (en) * 2003-07-11 2013-11-26 Novavax, Inc. Functional influenza virus-like particles (VLPs)
DE60330399D1 (de) 2003-07-29 2010-01-14 All India Inst Med Trichmikroskopie, kultur und polymerasekettenreaktion unter verwendung prozessierter klinischer proben und kit davon
CN101415443A (zh) * 2003-10-23 2009-04-22 阿尔扎公司 涂覆微喷射体的稳定dna组合物
JP2005154416A (ja) 2003-10-31 2005-06-16 Fuji Photo Film Co Ltd 核酸の分離精製方法、核酸分離精製カートリッジ、及び核酸分離精製キット
PT2336147E (pt) 2003-12-17 2014-07-16 Janssen Alzheimer Immunotherap Conjugados transportadores de péptidos beta imunogénicos e seus processos de produção
RU2267496C2 (ru) * 2004-01-15 2006-01-10 Сергей Иванович Черныш Противоопухолевые и антивирусные пептиды
EP1713508A2 (en) 2004-01-29 2006-10-25 Biosynexus Incorporated Use of amino-oxy functional groups in the preparation of vaccine conjugates
ITMI20040167A1 (it) 2004-02-04 2004-05-04 Univ Padova Metodo per l'estrazione simultanea di acidi nucleici da un campione biologico
EP1568369A1 (en) * 2004-02-23 2005-08-31 Boehringer Ingelheim Vetmedica Gmbh Use of meloxicam for the treatment of respiratory diseases in pigs
WO2005085274A1 (en) 2004-03-04 2005-09-15 The University Of British Columbia Toll-like receptor 2 (tlr-2) haplotypes predict outcome of patients
ATE497837T1 (de) 2004-04-09 2011-02-15 Vivebio Llc Vorrichtungen und verfahren für abnahme, lagerung und transport von biologischen proben
CN1968838B (zh) 2004-05-12 2010-07-07 夏洛特-梅克伦堡医院（商业用名：卡罗来纳医疗中心） 移动式医疗机构
US7776530B2 (en) * 2004-06-29 2010-08-17 Wallac Oy Integrated nucleic acid analysis
US20080260763A1 (en) * 2004-07-01 2008-10-23 The Regents Of The University Of California High Throughput Proteomics
CA2897112A1 (en) * 2004-10-05 2006-04-20 Fvg Limited Compositions comprising an antigen and a promiscuous t-cell epitope
US7648681B2 (en) 2004-12-01 2010-01-19 Meridian Bioscience, Inc. Specimen collection system
US7329493B2 (en) 2004-12-22 2008-02-12 Asiagen Corporation One-tube nested PCR for detecting Mycobacterium tuberculosis
WO2006104615A2 (en) * 2005-02-24 2006-10-05 University Of Massachusetts Influenza nucleic acids, polypeptides, and uses thereof
US20060286557A1 (en) 2005-06-15 2006-12-21 Basehore Lee S Combined lysis and PCR buffer
US7452284B2 (en) 2005-10-03 2008-11-18 Frank Pepe Golf club rest
WO2007051036A2 (en) * 2005-10-26 2007-05-03 Protelix, Inc. Influenza combinatorial antigen vaccine
US9308252B2 (en) 2005-10-27 2016-04-12 Cook Biotech, Inc. Extracellular matrix materials as vaccine adjuvants for diseases associated with infectious pathogens or toxins
AU2006311752A1 (en) * 2005-11-07 2007-05-18 Sidney Kimmel Cancer Center CD40 ligand fusion protein vaccine
US7914797B2 (en) * 2005-12-06 2011-03-29 Yeda Research And Development Co. Ltd. At The Weizmann Institute Of Science Influenza vaccine
US20070172835A1 (en) * 2006-01-20 2007-07-26 The Regents Of The University Of California Multiplex detection of respiratory pathogens
GB0613977D0 (en) 2006-02-07 2006-08-23 Peptcell Ltd Peptide sequences and compositions
US20070202511A1 (en) * 2006-02-28 2007-08-30 Sigma-Aldrich Co. Methods and compositions for the rapid isolation of small RNA molecules
TW200745158A (en) * 2006-03-07 2007-12-16 Vaxinnate Corp Compositions that include hemagglutinin, methods of making and methods of use thereof
US9072701B2 (en) 2006-04-21 2015-07-07 St. Jude Children's Research Hospital Avian influenza viruses, vaccines, compositions, formulations, and methods
EP2016199A4 (en) 2006-05-11 2009-12-30 Geneohm Sciences Inc METHODS OF 100% DETECTION OF THE IDENTITY OF A SEQUENCE FOR VARIOUS GENOMES
AU2007314550A1 (en) 2006-05-18 2008-05-08 Pharmexa Inc. Inducing immune responses to influenza virus using polypeptide and nucleic acid compositions
US20080050737A1 (en) * 2006-05-23 2008-02-28 Boaz Arieli Ambient Temperature Stable Kits for Molecular Diagnostics
US8287266B2 (en) 2006-06-16 2012-10-16 GKN Aerospace Services Structures, Corp. Device for performing consolidation and method of use thereof
KR101586968B1 (ko) 2006-08-09 2016-01-20 메디뮨 엘엘씨 인플루엔자 헤마글루티닌 및 뉴라미니다제 변이체
US7649559B2 (en) 2006-08-30 2010-01-19 Aptina Imaging Corporation Amplifier offset cancellation devices, systems, and methods
US8097419B2 (en) 2006-09-12 2012-01-17 Longhorn Vaccines & Diagnostics Llc Compositions and method for rapid, real-time detection of influenza A virus (H1N1) swine 2009
US20090098527A1 (en) * 2006-09-12 2009-04-16 Fischer Gerald W Biological organism identification product and methods
US8080645B2 (en) 2007-10-01 2011-12-20 Longhorn Vaccines & Diagnostics Llc Biological specimen collection/transport compositions and methods
US8652782B2 (en) 2006-09-12 2014-02-18 Longhorn Vaccines & Diagnostics, Llc Compositions and methods for detecting, identifying and quantitating mycobacterial-specific nucleic acids
US20120107799A1 (en) 2010-10-29 2012-05-03 Longhorn Vaccines & Diagnostics LLC. Disposable, rapid extraction apparatus and methods
US20080107687A1 (en) 2006-11-06 2008-05-08 Herve Poulet Feline vaccines against avian influenza
JP5376790B2 (ja) 2006-12-04 2013-12-25 キヤノン株式会社 センサ、及びその製造方法
GB0711683D0 (en) * 2007-06-16 2007-07-25 Enigma Diagnostics Ltd Compositions
BRPI0815008B8 (pt) 2007-08-02 2021-05-25 Biondvax Pharmaceuticals Ltd vacinas multiméricas com múltiplos epítopos contra influenza
KR20100058541A (ko) * 2007-08-15 2010-06-03 아뮤닉스 인코포레이티드 생물학적 활성 폴리펩티드의 특성을 변경하기 위한 조성물 및 방법
AU2008293504B2 (en) 2007-08-27 2012-04-12 Longhorn Vaccines & Diagnostics, Llc Immunogenic compositions and methods
DK2535428T3 (en) 2007-10-01 2015-11-23 Longhorn Vaccines & Diagnostics Llc Biological prøvesamlings- and transport system, and methods of using
GB0723439D0 (en) 2007-11-29 2008-01-09 Univ London Pharmacy Naphthalene diimide compounds
EP2528622A2 (en) * 2010-01-26 2012-12-05 The Regents of the University of Colorado Influenza virus epitopes templated into double-stranded coiled coils and use thereof in immunization
EP2582850B1 (en) * 2010-06-21 2016-11-09 Life Technologies Corporation Compositions, kits, and methods for synthesis and/or detection of nucleic acids
US20120177701A1 (en) * 2010-12-31 2012-07-12 Selecta Biosciences, Inc. Compositions comprising immunostimulatory nucleic acids and related methods
CN104203272A (zh) * 2012-01-26 2014-12-10 长角牛疫苗和诊断有限责任公司 复合抗原序列及疫苗

Also Published As

Publication number Publication date
RU2468034C2 (ru) 2012-11-27
WO2009029686A1 (en) 2009-03-05
AU2008293504B2 (en) 2012-04-12
US20090081202A1 (en) 2009-03-26
US20150024038A1 (en) 2015-01-22
EP3058954B1 (en) 2017-03-01
EP2772267A3 (en) 2014-12-10
EP2772267A2 (en) 2014-09-03
CA2697373C (en) 2019-05-21
EP3058954A3 (en) 2016-11-02
US9777045B2 (en) 2017-10-03
US9388220B2 (en) 2016-07-12
AU2008293504A1 (en) 2009-03-05
ZA201001412B (en) 2012-07-25
US20160368950A1 (en) 2016-12-22
CA2976814A1 (en) 2009-03-05
CA2697373A1 (en) 2009-03-05
EP2185196B1 (en) 2014-06-11
EP2772267B1 (en) 2016-04-27
CA2976814C (en) 2022-12-13
US8821885B2 (en) 2014-09-02
ZA201203709B (en) 2013-06-26
EP3058954A2 (en) 2016-08-24
EP2185196A1 (en) 2010-05-19

Similar Documents

Publication Publication Date Title
RU2010111758A (ru) Иммуногенные композиции и способы
WO2021243974A1 (zh) 一种SARS-CoV-2的融合蛋白及其疫苗组合物
CN116143938B (zh) 一种covid-19亚单位疫苗及其制备方法与应用
KR100703571B1 (ko) 인플루엔자에 대한 펩티드-기초 백신
JP2013241442A5 (ru)
EA022788B1 (ru) Новые терапевтические и диагностические средства
CN106794236B (zh) A群链球菌疫苗
US20220054625A1 (en) Immunogenic composition
US20240166697A1 (en) Immunogenic Compositions to Treat and Prevent Microbial Infections
JP2011506433A (ja) 改変された免疫組成物
Kim et al. MCMV-based vaccine vectors expressing full-length viral proteins provide long-term humoral immune protection upon a single-shot vaccination
Ma et al. Immunogenicity of multi-epitope vaccines composed of epitopes from Streptococcus dysgalactiae GapC
Schulze et al. A prime-boost vaccination protocol optimizes immune responses against the nucleocapsid protein of the SARS coronavirus
Choi et al. Protective immunity of 56-kDa type-specific antigen of Orientia tsutsugamushi causing scrub typhus
KR20200046059A (ko) 그룹 a 스트렙토코쿠스에 대한 면역원성 펩티드
US20210292398A1 (en) Streptococcal toxic shock syndrome
CN105348373B (zh) 猪链球菌血清3型的粘附性抗原ssust3_1962及其制备方法和应用
US20090155295A1 (en) Vaccine
AU758555B2 (en) Peptides
RU2775621C2 (ru) Иммуногенный пептид против стрептококков группы а
US20240009301A1 (en) Immunogenic compositions for producing neutralising antibodies against sars-cov
KR101922414B1 (ko) 클로스트리디움 퍼프린젠스의 알파 독소를 표면 발현하는 재조합 독소원성 대장균
JPH08198774A (ja) Ｄｎａワクチン
Cicin-Sain et al. MCMV based vaccine vectors expressing full-length viral proteins provide long-term humoral immune protection upon a single-shot vaccination
CN115947801A (zh) 一种流感病毒通用和冠状病毒联合多肽及其疫苗的应用